GSK gives up on Horizant as XenoPort decides to go it alone
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and XenoPort have decided to resolve their differences over Horizant (gabapentin enacarbil) extended-release tablets by terminating their collaboration. XenoPort now intends to hire a contract sales force in an attempt to do a better job on its own of commercialising the product.